Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody
Tamara Mateu‐Albero, Raquel Juárez-Sánchez, Javier Loscertales, Wim Mol, Fernando Terrón, Cecilia Muñoz‐Calleja, Carlos Cuesta‐Mateos
Topics & Concepts
IbrutinibChronic lymphocytic leukemiaC-C chemokine receptor type 7MedicineCancer researchBruton's tyrosine kinaseChemoimmunotherapyImmunologyLeukemiaOncologyInternal medicineTyrosine kinaseChemokine receptorChemokineReceptorChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders